VIR - Lilly and Regeneron monoclonal antibodies among preferred therapies in EU against COVID-19

Dr_Microbe/iStock via Getty Images On Tuesday, the European Commission listed four monoclonal antibody treatments and a repurposed drug against COVID-19 as it plans to create an initial portfolio of preferred drugs for the disease, Reuters reports. With the selection, the regional body aims to speed up regulatory approvals and devise a joint procurement plan for the treatments on behalf of member countries. The anti-inflammatory drug Baricitinib (Olumiant) developed by Eli Lilly ([[LLY]] +0.8%) and Incyte ([[INCY]] -1.0%) is already approved for rheumatoid arthritis in the EU. It is indicated for hospitalized patients on oxygen. Antibody therapies from GlaxoSmithKline ([[GSK]] +0.1%)/ Vir Biotechnology ([[VIR]] +1.0%), Eli Lilly, Regeneron ([[REGN]] +0.2%) and Celltrion are also included in the list. They are indicated for the early stage of the disease and currently subject to the EMA’s rolling review. Remdesivir from Gilead ([[GILD]] -0.1%) remains the only approved COVID-19 treatment in the region.

For further details see:

Lilly and Regeneron monoclonal antibodies among preferred therapies in EU against COVID-19